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A genetic vaccine for West Nile virus (WN) has been synthesized with the WN premembrane-envelope (WN preM-E) gene sequences
encoded as a chimera with the transmembrane and carboxyl terminal domains of the lysosome-associated membrane protein (LAMP). The
LAMP sequences are used to direct the antigen protein to the major histocompatibility class II (MHC II) vesicular compartment of transfected
professional antigen-presenting cells (APCs). Vaccine constructs encoding the native WN preM-E and WN preM-E/LAMP chimera were
synthesized in pVAX1 and pITR plasmid backbones. Extracts of human fibroblast 293 and monkey kidney COS-7 cells transfected with the
WN preM-E/LAMP chimera constructs contained much greater amounts of E than did the cells transfected with constructs encoding the
native WN preM-E. This difference in the concentration of native E and the E/LAMP chimera in transfected cells is attributed to the secretion
of native E. The amount of preM protein in cell extracts, in contrast to the E protein, and the levels of DNA and RNA transcripts, did not
differ between WN preM-E- and WN preM-E/LAMP-transfected cells. Additionally, confocal and immunoelectron microscopic analyses of
transfected B cells showed localization of the WN preM-E/LAMP chimera in vesicular compartments containing endogenous LAMP, MHC
II, and H2-M, whereas native viral preM-E lacking the LAMP sequences was distributed within the cellular vesicular network with little
LAMP or MHC II association. Mice immunized with a DNA construct expressing the WN preM-E/LAMP antigen induced significant
antibody and long-term neutralization titers in contrast to the minimal and short-lived neutralization titer of mice vaccinated with a plasmid
expressing the untargeted antigen. These results underscore the utility of LAMP targeting of the WN envelope to the MHC II compartments
in the design of a genetic WN vaccine.
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The Flaviviridae family of viruses includes several
important pathogens that cause diseases of major public
health importance, including yellow fever, dengue, Japanese
encephalitis (JE), and West Nile (WN) viruses. As there are
no antiviral drugs active against flaviviruses, vaccination
remains the most effective means of disease prevention,
with the development and application of inactivated and live
attenuated virus vaccines for use in humans against yellow
fever, tick-borne encephalitis, and Japanese encephalitis
viruses (Barrett, 2001; Pugachev et al., 2003). These
vaccines have proven efficacy; however, adverse reactions
have been reported and there is a potential risk of gene
reversion or recombination to a virulent virus (Berkhout et
al., 1999; Gundlach et al., 2000; Liu et al., 2003). Thus, the
search for the development of safer forms of vaccines
continues, including genetic vaccines encoding specific
viral sequences that offer many possible advantages
(Donnelly et al., 2003; Gurunathan et al., 2000; Hall et
al., 2003; Liu, 2003; Putnak et al., 2003).
Among flaviviruses, West Nile (WN) has recently
assumed increasing importance because of its global spread.
WN is an important human pathogen that is maintained in
nature as a mosquito-borne viral disease of birds with
humans and other mammals as occasional hosts (Petersen et
al., 2003). The virus is widely distributed in Africa and
Europe, and the rapid spread since 1999 in the United
States is attributed to viremic migratory birds as well as
enhanced mosquito distribution (Hubalek et al., 2000;
Nedry and Mahon, 2003; Rappole and Hubalek, 2003).
Research in the development of a variety of WN vaccines
has been reported from several laboratories. Attenuated,
live virus vaccines include a replicon vaccine vector
encoding the infectious full-length RNA genome of Kunjin
(Hall et al., 2003) and chimera viruses bearing the
membrane precursor and envelope protein genes of WN
on backbones of dengue (Pletnev et al., 2003) and yellow
fever viruses (Arroyo et al., 2001). DNA vaccines encoding
WN virus proteins that induced protection in animal
challenge systems have also been described (Davis et al.,
2001; Turell et al., 2003).
In this report, we describe the development of a West
Nile virus genetic vaccine based upon a molecular adjuvant
methodology designed to target DNA-encoded antigens to
compartments of antigen-presenting cells (APCs) that
contain the major histocompatibility class II (MHC II)
protein known to function in antigen processing and
presentation to CD4+ T cells (Drake et al., 1999; Geuze,
1998; Kleijmeer et al., 1997, 2001; Turley et al., 2000).
DNA constructs are synthesized with the antigen sequences
linked to those of the lysosomal-associated membrane
protein (LAMP) (Chen et al., 1985) containing the LAMP
targeting signals (Guarnieri et al., 1993) that direct the
LAMP/antigen chimera to specialized endosomal–lysoso-
mal compartments that contain MHC II. LAMP targeting ofthe WN premembrane-envelope (preM-E) protein is shown
to elicit a significant and long-lasting neutralizing antibody
response in mice as compared to DNA encoding the wild-
type WN preM-E. Several previous studies have also
demonstrated the enhanced antigen-specific immune
responses of such antigen/LAMP chimeras of vaccinia
virus vector and DNA plasmid vaccine preparations
(Marques et al., 2003; Ruff et al., 1997; Wu et al., 1995),
including studies of a dengue virus vaccine (Lu et al., 2003;
Raviprakash et al., 2001). The function of LAMP targeting
sequences to increase the trafficking of genetic vaccines to
the MHC II compartment can be viewed as particularly
important for the activation of CD4+ T cells and the
development of memory B and CD8+ T cells, an essential
criterion for an effective prophylactic vaccine. An excep-
tional additional finding in these studies was the increased
cellular concentration of the preM-E/LAMP chimera
protein in transfected cells as compared to the native
preM-E. Unlike the native WN E that is secreted from the
cell, the WN preM-E/LAMP chimera antigen is present in
the MHC II compartment of transfected B cells as shown
by confocal and immunoelectron microscopy (IEM) using
double and triple labeling for the chimeric viral/LAMP,
MHC II, and H-2M proteins, the latter of which is closely
related to antigen presentation (Neefjes, 1999). These
results suggest the application of the WN preM-E/LAMP
chimera genetic vaccine as a candidate for higher animal
challenge studies in the development of a WN DNA
vaccine.Results
Genetic vaccine plasmid constructs and expression of the
WN preM-E and preM-E/LAMP proteins
Expression plasmids of pVAX-1 and pITR containing the
native WN preM-E sequences and the chimera containing
the LAMP transmembrane and cytoplasmic domains replac-
ing the corresponding WN E sequences (Fig. 1A) were
constructed as described in Materials and methods. Vali-
dation of plasmid protein expression was conducted by
transfection of human fibroblast 293 and monkey kidney
COS-7 cells followed by SDS-PAGE of total cell extracts
and Western blotting (Fig. 1B). Transfected cells showed
protein bands corresponding to the processed forms of the
preM and E proteins. Additional bands stained with the
polyclonal antiserum were nonspecific and present in
extracts of cells transfected with the empty vector. An
important finding was the enhanced cellular concentration
of E as an E/LAMP chimera. The amount of steady-state E
protein was markedly lower in cells transfected with the
native preM-E construct as compared to that present in cells
transfected with the preM-E/LAMP chimera construct.
Overexposed Western blot analysis showed only a slight
band of the E protein in lanes containing lysates from cells
Fig. 1. Construction and expression of WN preM-E and preM-E/LAMP plasmids. (A) Schematic representation of the plasmids used in this study. The preM-E
and preM-E/LAMP DNAs were constructed in the pVAX1 vector as described in Materials and methods. The pVax-WN plasmid encodes the unmodified WN
preM-E, and the preM-E chimera pVax-WNL modified to include the LAMP transmembrane and carboxyl terminal signal sequences. Boxed areas represent the
open reading frames as indicated. The arrows indicate the positions of the various sequences: signal sequence for endoplasmic reticulum translocation (SS),
signal peptidase cleavage site between preM-E (CS), and the LAMP transmembrane and carboxyl terminal signal sequences (TM-YQTI). (B) Western blot
analysis. Human 293 cells were transfected with the vector, wild-type WN preM-E, and preM-E/LAMP chimera DNA plasmids constructed in pVAX1 and
pITR expression vectors as indicated, and probed with anti-WN hyperimmune ascitic fluid. The molecular weight markers are shown on the left. E and preM
denote the positions of expressed WN envelope and premembrane proteins. Similar results were obtained from monkey kidney COS-7 cells transfected with the
above plasmids. (C) Specific detection of WN RNA transcripts. Total RNA and DNA of transfected cells were analyzed by real-time PCR. The WN E
fragments were obtained only from total RNA of cells transfected with pVax-WN (lane 2) and pVax-WNL (lane 3), and not from cells transfected with the
vector (lane 1). The cDNA amplifications were not due to contaminating transfected plasmids. Lanes 4–6 indicate amplification of the pVAX1 vector backbone
from total DNA of cells transfected with the vector, pVax-WN, and pVax-WNL, respectively. All of the above results are representative of three independent
experiments. M, 100 bp DNA marker.
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steady-state level of preM protein, which was not signifi-
cantly different between the two preM-E and preM-E/
LAMP cell lysates.
Further analysis to determine if differences in the
amounts of E protein could be attributed to the amount of
plasmid or mRNA transcription of the expression of native
preM-E and preM-E/LAMP was conducted by quantitative
real-time PCR analysis of cellular DNA and RNA. Total
RNA and DNAwere isolated simultaneously from the same
COS-7 cells transfected with either pVax-WN or pVax-
WNL. Specific primers were used to determine the amount
of intracellular plasmid in the transfected cells. When
normalized to the total amount of genomic DNA recovered,
there was no significant difference in the amounts of
plasmid DNA in cells transfected with pVax-WN or pVax-Fig. 2. Confocal microscopy of endogenous LAMP, MHC II, and H-2M, andWN an
pVax-WNL plasmids, were stained for the WN (red) and endogenous LAMP, MH
visualized by superimposing images of the WN antigens with the endogenous prot
antigen showed a reticular distribution and did not colocalize with the endogenou
expression of wild-type WN antigens was low, pixel distribution was adjusted with
chimera WN preM-E/LAMP antigen showed a punctuated and vesicular profile an
The endogenous MHC II and H-2M showed colocalization internal of the B cells (
endogenous H-2M proteins (M–O). Image processing to adjust equal pixel densityWNL constructs. The expression levels of WN RNA
transcribed from pVax-WN and pVax-WNL plasmids in
transfected COS-7 cells were also compared and no
significant differences were observed (data not shown).
Validation that the amplifications from reversed-transcribed
RNA samples were not due to contaminating plasmids was
conducted by performing reverse transcription (RT) in the
presence or absence of random primers, followed by PCR
using WN E-specific primers that would yield a product of
384 bp. Amplifications were observed only with samples
reverse transcribed with random primers, indicative of a lack
of contamination from plasmids in the total RNA samples.
Reverse-transcribed WN RNA by PCR was detectable only
from cells transfected with pVax-WN and pVax-WNL, and
not from cells transfected with a control vector (Fig. 1C) or
from mock-transfected cells (data not shown).tigens in B cells. Mouse LB27.4 B cells, transfected with either pVax-WN or
C II, or H-2M (green) molecules. Colocalization of the viral antigens was
eins and shown as yellow in the merged images. The wild-type WN preM-E
s MHC II (A–C) or LAMP (D–F) molecules. Note that as the steady-state
respect to endogenous LAMP and MHC II to enable merging. In contrast, the
d colocalized extensively with endogenous MHC II (G–I) and LAMP (J–L).
P–R). The preM-E/LAMP viral antigen was observed to colocalize with the
distribution was carried out on Adobe Photoshop 6.0.
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MHC II, and H-2M in B cells
The cellular trafficking of the unmodified and LAMP-
targeted WN preM-E protein was analyzed by comparing
the cellular steady-state localization of the transgene-
expressed viral proteins to the localization of endogenous
LAMP, MHC II, and H-2M molecules by confocal micro-
scopy and immunoelectron microscopy (IEM). The mouse
B lymphoma cell line (LB 27.4) used in this study exhibits
the phenotype of B cells similar to A20 and IIA1.6 B cells
(Lankar et al., 2002). Mouse LB27.4 B cells were trans-
fected with either the unmodified pVax-WN (preM-E) or
pVax-WNL (preM-E/LAMP). Confocal microscopy
showed the reticular, cytoplasmic distribution of the trans-
gene wild-type WN preM-E protein with no significant
colocalization with endogenous MHC II or LAMP mole-
cules (Figs. 2A–F). In contrast, the WN preM-E/LAMP
protein was extensively colocalized with endogenous
LAMP and MHC II molecules in a typical lysosomal
distribution (Figs. 2G–L). The localization of the preM-E/
LAMP was also studied in relation to H-2M, an essential
mediator for MHC II peptide loading and found predom-
inantly in the late MHC II-containing compartments
(MIICs; Geuze, 1998; Neefjes, 1999). Endogenous H-2M
molecules in B cells are colocalized with the endogenousFig. 3. Immunoelectron microscopic images (IEM) of B cells transfected with pVa
pVax-WN and immunolabeled with ID4B antibody (15 nm, anti-mLAMP), M5/11
images of B cells transfected with pVax-WNL and immunolabeled with ID4B an
6B6C-1 (5 or 10 nm) showing the WN protein in the endogenous MIIC. The arr
MHC II proteins, respectively. PM, plasma membrane; MIIC, MHC II containingMHC II molecules (Figs. 2P–R), consistent with the
findings in A20 and IIA1.6B cells (Lankar et al., 2002).
The WN preM-E/LAMP protein was found to colocalize
with the endogenous H-2M (Figs. 2M–O) as well as the
MHC II, further demonstrating the altered targeting of the
preM-E/LAMP protein to antigen-presenting compartments.
These findings are representative of several independent
experiments.
Immunoelectron microscopy (IEM) demonstration of WN
preM-E/LAMP in MHC II compartments
The ability of the LAMP carboxyl terminal targeting
signal to direct trafficking of the viral antigen to the
MHC II compartment was further studied in detail by
IEM on ultrathin sections of transfected B cells (Fig. 3).
Previous studies by others have shown MHC II present in
B cells in classical multilaminar (MLC) and multi-
vesicular (MVC) vesicles and are involved in antigen
processing and MHC II presentation (MIICs) (Kleijmeer
et al., 1997). The transgene WN preM-E/LAMP chimera
antigen was also present in these MIIC vesicles and
colocalized with endogenous LAMP and MHC II
molecules (Figs. 3D–F). In contrast, unmodified wild-
type WN preM-E antigen was distributed throughout the
cytoplasm as well as at the peripheral plasma membranex WN and pVax-WNL. (A–C) Ultrathin sections of B cells transfected with
4 antibody (15 nm, anti-MHC II), and 6B6C-1 (10 nm, anti-E). (D–F) IEM
tibody (15 nm), M5/114 antibody (15 nm), K553 (10 nm, anti-H2M), and
owhead, notched arrow, and star indicate representative WN E, H-2M, and
compartment.
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colocalized with endogenous LAMP nor located within
the MIICs of B cells (Figs. 3A–C). Triple immunolabel-
ing also showed the presence of the chimera WN preM-E/
LAMP antigen with endogenous H-2M molecules as well
as with MHC II (Fig. 3F).
Enhanced immune response of mice to a genetic vaccine
with the WN viral preM-E sequence fused to the LAMP
targeting motif
The immune response to LAMP-modified WN preM-E
protein was analyzed with mice and followed for 2 years
after immunization. Four groups of five animals each were
injected subcutaneous at the base of the tail with 50 Ag of
endotoxin-free plasmid DNA on days 0, 21, 42, and 63
(Fig. 4A) with pVAX vector expression constructs encod-
ing: (a) the negative control pVax1 vector alone; (b)
unmodified preM-E sequences (pVax-WN); and (c) preM-
E fused to the LAMP transmembrane and cytoplasmic
sequences (pVax-WNL). As a positive control, animals
were injected with 10 Ag total WN virion protein emulsified
with complete Freund’s adjuvant and subsequently boosted
with the same preparation with incomplete Freund’s
adjuvant. The antibody endpoint titers of individual mouse
in each group were measured at days 55, 62, 90, and 125 by
ELISA (Fig. 4B). At day 55, two of the five unmodified
preM-E vaccinated mice showed appreciable endpoint
titers, which increased to three mice at day 62. However,Fig. 4. Immunization protocol and antibody responses of individual mouse immun
Mice (n = 5) were immunized on days 0, 21, 42, and 63 with the WN plasmids an
from days 1 to 730 as indicated. (B) The endpoint titers of WN-specific IgG res
represents the endpoint titer of serum obtained from individual mice in their res
samples collected from groups of mice immunized with pVax-WN, pVax-WNL, a
sera dilution. The percentage of virus neutralization was determined for each gro
deviation.the antibody responses of these mice were not sustained,
and by day 90 onwards, these mice no longer showed
significant WN-specific endpoint antibody titers. In con-
trast, all mice immunized with pVax-WNL showed anti-
body responses at day 55, with increasing endpoint titers
from days 55 to 125.
Neutralizing antibodies, determined by a standard plaque
reduction neutralization test (PRNT), were assayed with
pooled sera of each group of mice starting with sera
dilutions from 1/20 to 1/1280 in 2-fold serial increments.
None of the sera samples obtained from the WN preM-E
group, collected at days 62, 90, and 125, showed a
significant difference in neutralizing antibody responses
compared to the negative control group immunized with
pVAX1 (Table 1). In contrast, there was a significant
neutralization titer response in sera from mice immunized
with the WN preM-E/LAMP construct at days 90 and 125.
This neutralization titer response from mice immunized with
WN preM-E/LAMP construct was comparable to the
positive control group of mice immunized with the WN
virion proteins in Fruend’s adjuvant. No significant neu-
tralization titer was detected in the pooled sera obtained at
day 62 despite high WN-specific antibody titers in two of
the five immunized mice. The presence of memory B cell
response was assessed with the groups of mice immunized
at day 716, 19 months after the last boost, and the blood
collected 2 weeks later at day 730. While there was no
significant neutralization with sera from the WN preM-E
group, there was appreciable neutralization with sera fromized with pVax-WN and pVax-WNL plasmids. (A) Immunization schedule.
d virion proteins as described in Materials and methods, and blood collected
ponses obtained from sera collected on days 55, 62, 90, and 125. Each bar
pective groups. (C) Plaque reduction neutralization assay at day 730. Sera
nd virion proteins were pooled and used in the PRNT assay, starting at 1:20
up at various dilutions and shown as a mean percentage with one standard
Table 1
50% virus neutralization titers (PRNT50)
Groups Day 62 Day 90 Day 125 Day 730
pVAX1 b20 b20 b20 ND
pVax-WN b20 b20 b20 b20
pVax-WNL b20 66 72 46
WN virus b20 74 75 145
Sera samples from each group, collected on days 62, 90, 125, and 730, were
analyzed by plaque reduction neutralization (PRNT) assay. Serum from
individual mice in each group was pooled, irrespective of the seroconver-
sion status of the sera, to obtain a representative average titer within the
experiment. The serum titer that was able to reduce the plaque number
formed by 50% (PRNT50) is indicated.
A. Anwar et al. / Virology 332 (2005) 66–7772the WN preM-E/LAMP group (Fig. 4C). This titer was
however significantly lower than the positive control group
(Table 1).Discussion
This report expands on our previous work describing
genetic vaccines based upon DNA constructs encoding the
antigen as a protein chimera containing sequences of the
LAMP lysosomal membrane proteins (Chikhlikar et al.,
2004; de Arruda et al., 2004; Lin et al., 1996; Lu et al.,
2003; Marques et al., 2003; Raviprakash et al., 2001;
Rowell et al., 1995; Ruff et al., 1997; Wu et al., 1995).
These LAMP sequences target the antigen chimera to
cellular endosomal/lysosomal compartments that in APCs
(B, macrophage, and dendritic cells) contain both LAMP
and MHC II molecules and function in proteolytic process-
ing of antigen proteins to peptide epitopes and in epitope
presentation to CD4+ T cells (Amigorena et al., 1994; Drake
et al., 1999; Geuze, 1998; Kleijmeer et al., 1997, 2001;
Turley et al., 2000). Delivery of MHC II molecules to these
compartments is directed by an associated invariant chain (I-
chain) that is degraded in endosomes to a peptide sequence
(clip) that remains bound to the class II peptide loading
groove until replaced by antigen protein epitopes in a
process facilitated by mouse H2-M or human HLA-DM
proteins (Busch et al., 2000; Hiltbold and Roche, 2002; Vogt
and Kropshofer, 1999; Vogt et al., 1999). LAMP molecules
are directed to lysosomes by a tyrosine-based carboxyl
terminal targeting sequence that functions in the context of
the cytoplasmic domain of the molecules (Guarnieri et al.,
1993). Conventionally, antigens directed to the LAMP/
MHC II compartment(s) are bforeignQ molecules delivered
by binding to specialized plasma membrane endocytic
receptors of dendritic and other phagocytic cells (Mahnke
et al., 2000; Mellman and Steinman, 2001; Parkin and
Cohen, 2001). This is to be distinguished from antigen/
LAMP chimera proteins that are recombinant endogenous
molecules, with no natural counterpart, that enter the cell
vesicular compartment by the endoplasmic reticulum trans-
location signal sequence, pass through the Golgi apparatus,and are directed to lysosomes by specific adaptor protein
association with the LAMP carboxyl terminal targeting
sequence (Bonifacino and Dell’Angelica, 1999; Bonifacino
and Traub, 2003). Thus, the MHC II, dendritic cell antigen
receptors, and LAMP each use different vesicular trafficking
mechanisms to reach the compartment where antigen
peptide epitopes bind to MHC II molecules. In this study,
we have analyzed the localization of endogenous LAMP,
MHC II, H2-M, and the transgene WN E/LAMP of
transfected B cells by combined confocal light microscopy
and immunoelectron microscopy. The data show remarkable
confocal colocalization of the preM-E/LAMP transgene
product with B cell MHC II, LAMP-1, and H2-M proteins.
Detection of the transgene WN E protein was based on
binding of monoclonal antibody 6B6C-1 that reacts with
flaviviral E protein (Roehrig, 2003; Roehrig et al., 1983). It
is highly likely that this antibody binds only to E/LAMP
chimera or intact or perhaps partially degraded E and not to
epitope peptides associated with the MHC II. It would
therefore appear that it is the unprocessed or perhaps only
slightly processed transgene E protein that is detected
colocalized with endogenous LAMP, MHC II, and H2-M.
Thus, the distribution of transgene E/LAMP correlated with
that of the endogenous proteins in internal endocytic/
lysosomal compartments, and not with the MHC II
molecules present on the cell surface as a result of the
transport of peptide-loaded molecules to the plasma
membrane. At the electron microscopy level, the site of
colocalization of the preM-E/LAMP with the endogenous
MHC II, LAMP-1, and H2-M molecules was predominantly
in unique electron dense multilaminar structures corre-
sponding to late MIICs and, in some cases, late endosomes
and exososome-like multivesicular compartments (Geuze,
1998; Kleijmeer et al., 1997). This distribution of the preM-
E/LAMP was markedly different from that of the unmodi-
fied preM-E protein that was instead distributed mainly
within the vesicular structures of the ER, Golgi complex,
trans-Golgi network, and secretory vesicles, consistent with
earlier reports of WN structural proteins being transported
from the perinuclear region, along the endoplasmic retic-
ulum (ER), to the plasma membrane during its morpho-
genesis (Chu and Ng, 2002; Mackenzie and Westaway,
2001). There was little apparent colocalization with endog-
enous LAMP or MHC II, except possibly with MHC II at
the plasma membrane and infrequently with LAMP,
attesting to the separate vesicular pathways of these
molecules in post-Golgi trafficking. On this basis, we
speculate that access of native preM-E encoded by DNA
vaccines to the MHC II would entail a mechanism not
observed in these transfected B cells, such as uptake of
secreted protein or alternative processing pathways in other
transfected APCs.
The rationale for targeting antigens to the MIICs of APCs
is to increase the amount of epitopes loaded onto the MHC
II molecules and thus more readily reaching the CD4+ T cell
receptor triggering threshold and antigen-specific CD4+ T
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of memory B cell and CD8+ T cell responses (Chan et al.,
2001; Maecker et al., 1998; Tanchot and Rocha, 2003). This
hypothesis is supported by evidence that LAMP-antigen
chimera vaccines result in enhanced CD4+ T cell responses
(Marques et al., 2003) and an increased number of antigen
MHC II epitopes (Fernandes et al., 2000) as compared to the
corresponding native antigens. When evaluated for the
effects on the humoral immune response in repeated
immunization studies, mice immunized with the pVax-
WNL DNA construct showed significantly higher and more
sustained antibody titers. While the total WN-specific IgG
titers of all mice immunized with pVax-WNL DNA
increased progressively after the second and third DNA
boosts, peaking at day 90 postvaccination, the antibody
response from mice immunized with the pVax-WN DNA
peaked earlier after the second DNA boost and subsequently
showed a concomitant decline in sera titers. This low and
unsustained immune response has been reported for several
DNA vaccines encoding native antigens of other proteins
(de Arruda et al., 2004; Fournillier et al., 1999; Martins et
al., 1995; Vidalin et al., 2000). When compared with mice
immunized with the wild-type pVax-WN DNA construct,
the levels of neutralization antibodies elicited in mice
immunized with pVax-WNL were comparable to the
positive control mice immunized with the WN virions at
days 90 and 125, declining at day 730 postimmunization.
Although the level of neutralizing antibody response was
lower compared to the positive control at 2 years post-
immunization, pooled sera from pVax-WNL-vaccinated
mice still showed an augmented neutralizing antibody titer
in contrast to pooled sera from pVax-WN-vaccinated mice.
This maintenance of a long-term immune response was also
observed in our previous study with the dengue preM-E/
LAMP DNA vaccine, where a high level of neutralizing
antibody was maintained over a period of 1 year post-
immunization (Lu et al., 2003). In another study of a West
Nile preM-E DNA vaccine (Davis et al., 2001), the mouse
neutralizing antibody response to the vaccine delivered by
electrotransfer was high compared to that reported here.
Although it is not possible to directly compare results
between different immunization protocols, immunization by
electrotransfer is reported to greatly increase DNA vaccine
efficacy as compared to the direct immunization used in this
study (Babiuk et al., 2002; Chang et al., 2001; Durieux et
al., 2002; Liu and Huang, 2002; Mir et al., 1999).
We attribute the low humoral response of mice immu-
nized with the native WN preM-E antigen to a diminished
trafficking to the MIICs, not to the possibly low steady-
state cytoplasmic level of the expressed E protein as
found with transfected cells in vitro. This low level of E
protein was shown not to be due to differences in the
transfection or transcriptional efficiencies and is thus
likely a posttranslational event. Taken together with the
Western analysis data, where the preM protein levels were
similar in pVax-WN- and pVax-WNL-transfected cellsdespite significant differences in the E protein, the data
are congruent with the secretion of the E protein,
confirming previously described studies by electron
microscopy (Ng et al., 1994), and by isolation of the
protein from the culture media of transfected COS-1 cells
(Davis et al., 2001). In addition, previous reports have
shown the secretion of the viral preM-E protein from cells
transfected with WN and other JE antigenic group DNA
constructs (Chang et al., 2000; Davis et al., 2001). In
contrast, the chimera E/LAMP protein containing the
carboxyl terminal transmembrane domain and targeting
sequences of LAMP directed to an endosomal/lysosomal
pathway and despite targeting to lysosomes has a higher
steady-state cellular concentration. Secretion of the E
protein could possibly increase its immunogenicity, as
several studies have shown that DNA vaccines encoding
secreted antigens generally induced higher immune
responses than the same antigens retained within the cell
(Andersson et al., 2000; Grode et al., 2002; Ma et al.,
2002; Riedl et al., 2002). In this case of the WN E, our
findings indicate that the secreted protein is not as
effective in eliciting an immune response as that targeted
directly to the MHC II compartment.Materials and methods
Cell lines and virus
The cell lines Vero, BHK-21, 293, COS-7, and LB27.4
were obtained from ATCC (Rockville, MD) and maintained
according to the supplier’s protocols. The West Nile virus
strain Wengler (obtained from Prof. Ng ML, National
University of Singapore) was propagated in Vero cells at
37 8C in 5% CO2 and the viral titer evaluated in BHK-21
cells by plaque assay as described (Gould and Clegg, 1985).
Construction of plasmid vaccines
Genomic RNA was extracted with guanidinium isothio-
cyanate, followed by delipidation and differential partition-
ing as described (Too and Maggio, 1995), and used as
template for the synthesis of WN cDNA by reverse
transcription (RT) using random hexamer primers and
MMuLV reverse transcriptase (Promega Corporation, Mad-
ison, WI) (Sambrook and Russell, 2001). The wild-type
plasmid containing the WN premembrane (preM) and
envelope (E) regions, inclusive of a 34 amino acids
endoplasmic reticulum translocation sequence present at
the carboxyl end of the capsid, was constructed by PCR
using WN-specific primers. The WN sequences were
amplified using primers that incorporated an ATG start site
in the context of the Kozak sequence and a translational stop
codon. PCR amplification was performed using the Expand
High Fidelity Taq polymerase (Roche Diagnostics GmbH,
Germany) and 50 nM of each primer. The amplified viral
A. Anwar et al. / Virology 332 (2005) 66–7774DNA fragment, extending from nucleotides 361 to 2457
(GenBank accession M12294), was cloned into pVAX1
(Invitrogen Life Technologies, Carlsbad, CA) to construct
the wild-type WN preM-E plasmid (pVax-WN). The
chimera WN preM-E/LAMP plasmid (pVax-WNL) was
constructed by replacing the transmembrane and carboxyl
terminal sequences of the E gene with the transmembrane
and carboxyl terminal domains of the mouse LAMP-1
(Guarnieri et al., 1993). All clones were verified by
sequencing. The viral sequences were also cloned into the
pITR vector (Kessler et al., 1996) to construct the pITR-WN
and pITR-WNL plasmids.
Cell transfection and immunochemical staining
The cellular localization of the expressed viral proteins in
the mouse B lymphoma cell line LB-27.4 was studied by
fluorescent confocal and immunoelectron microscopy. Cells
were transfected with the pVax-WN and pVax-WNL
plasmids using Lipofectamine PLUS (Invitrogen Life
Technologies) for 48 h according to the manufacturer’s
protocol. The expression of the recombinant viral proteins
was visualized by use of anti-WN hyperimmune ascitic fluid
(HIAF; ATCC) or 6B6C-1 (anti-Saint Louis Encephalitis
antibody cross-reactive to WN E protein; Chemicon
International Inc., Temecula, CA; Roehrig et al., 1983).
Localization of the viral proteins in relation to the MHC II-
containing compartments and lysosomes was studied by use
of the monoclonal antibodies M5/114.15.2 (anti-MHC II;
BD Biosciences, San Diego, CA), K553 (anti H-2M; gift
from Dr. L. Karlsson, R.W. Johnson Pharmaceutical
Research Institute, CA), and ID4B (IgG2a, anti-mouse
LAMP-1; (Chen et al., 1985; Hughes and August, 1982).
Confocal and immunoelectron microscopy
Confocal microscopy was carried out using an Olympus
IX70-Fluoview 300 system. Image processing to adjust
pixel density distribution was carried out on Adobe Photo-
shop 6.0 (Adobe System Corp., San Jose, CA). Immuno-
electron microscopy (IEM) was performed with transfected
cells fixed in a mixture of 4% paraformaldehyde and 0.2%
glutaraldehyde in PBS and incubated for 2 h at room
temperature. Fixed cells were processed for ultrathin
cryosectioning and immunogold labeling as described
previously (Kleijmeer et al., 1997). Briefly, cells were
washed with PBS and PBS containing 50 mM glycine,
pelleted, and embedded in 10% gelatin. Small blocks were
infiltrated with 2.3 M sucrose at 4 8C for at least 2 h and
then frozen in liquid nitrogen. The ultrathin cryosections
were prepared with a Leica Ultracut FCS Cryomicrotome
and retrieved with a 2:3 (vol/vol) mixture of 2% methyl-
cellulose and 2.3 M sucrose. Ultrastructural analysis was
performed with the same repertoire of antibodies used in
confocal microscopy. The sections were then double
immunolabeled with 10- and 15-nm gold particles or tripleimmunolabeled with 5-, 10-, and 15-nm gold particles (SPI
Supplies, PA, USA). The sections were contrast-stained,
embedded in a mixture of methylcellulose and uranyl
acetate, and viewed using a CM120 Twin Phillips electron
microscope.
RT-PCR and real-time quantitative PCR of transfected
nucleic acids
The total RNA and DNA of COS-7 cells transiently
transfected with the pVax-WN and pVax-WNL plasmids
were isolated simultaneously by use of TRIzol Reagent
(Invitrogen Life Technologies) according to manufacturer’s
instruction. The RNA was quantified by spectrophotometry
and gel electrophoresis. The RT reaction was performed at
42 8C with 2–5 Ag of total RNA, Improm-II reverse
transcriptase (Promega Corporation), and random hexamers
(Promega Corporation) in a total volume of 10 Al
(Sambrook and Russell, 2001). The primer sets WN-f/r
(WN-f, 5V TGAAGTGTCGGGTGAAG ATGG 3V, position
1811–1831; WN-r, 5V CTCTGAGTGTGGTGGTAAAGG
3V, position 2174–2194; GenBank accession no. M12294),
Vax-f/r (Vax-f, 5VTTCGCCACCTCTGACTT GAGC 3V,
position 2870–2890; Vax-r, 5V ATGGGCTATGAACTAAT-
GACC 3V, position 78–98; Invitrogen), and Actin-f/r (Actin-
f, 5VACAACGGCTCCGGCATGTGC 3V, position 32–51;
Actin-r, 5VGGTCATCTTTTCACGGTTGG 3V, position
341–360; GenBank accession no. AJ312092) were used in
real-time PCR studies to amplify the transcribed West Nile
E gene, intracellular plasmids, and the host actin gene,
respectively. All real-time quantitative PCR was performed
on the iCycler iQ Multi-Color Real Time PCR Detection
System (Bio-Rad, Hercules, CA) with the SYBR Green
PCR Master Mix containing AmpliTaq Gold DNA polymer-
ase (Applied Biosystem, Foster City, CA). The threshold
cycles (Ct) were calculated by use of the Optical interface
v3.0a (Bio-Rad). All real-time quantitative PCR was
performed under the following conditions: 95 8C for 10
min to activate the AmpliTaq Gold DNA polymerase,
followed by 50 cycles of 1 min denaturation at 95 8C, 30-s
annealing at 55 8C, and 30-s extension at 72 8C. Fluorescent
detection of SYBR Green I was carried out at the extension
phase. Linearized pVax-WN and an actin plasmid were used
as standards in the real-time PCR.
Western blot analysis of protein expression
The expression of WN viral proteins from pVax-WN,
pVax-WNL, pITR-WN, and pITR-WNL was analyzed by
Western blot of the transfected human fibroblast 293 and
monkey kidney COS-7 cell lines. Cells were seeded onto
60-mm plates and transfected with WN plasmids using
Polyfect Transfection reagent (Qiagen GmBH, Germany)
according to the manufacturer’s protocol. The proteins were
harvested 48 h posttransfection, resolved on a 12% SDS-
PAGE, and transferred onto a nitrocellulose membrane. The
A. Anwar et al. / Virology 332 (2005) 66–77 75WN proteins were detected by labeling with anti-WN HIAF
and SuperSignal West Pico Chemiluminescent Kit (Pierce,
Rockford, IL).
Mouse immunization
Endotoxin-free WN pVax plasmids used for immuniza-
tion experiments were prepared with the Qiagen Endofree
Plasmid Kit (Qiagen GmbH). Groups of five 6- to 8-week
female BALB/c mice were immunized by subcutaneous
injection at the base of the tail with 50 Ag of DNA in PBS.
Retro-orbital blood required for ELISA and neutralizing
antibody determinations was collected from individual
mouse prior to each immunization at days 55, 90, 125,
and 730 postimmunization. As a positive control, mice were
injected intraperitoneally (ip) with 10 Ag of WN virion
protein in complete or incomplete Freund’s adjuvant.
ELISA and neutralization assays
Anti-WN end-point titers (Crowther, 1995) of antibody
in the serum of each mouse were determined at 3-fold serial
dilutions by ELISA assay (Ansari et al., 1993) of antibody
binding to WN virion antigens purified by ultracentrifuga-
tion (Gould and Clegg, 1985). Virus neutralization titers
were measured by plaque reduction neutralization titer
(PRNT) assay in BHK-21 cells (Russell et al., 1967). All
statistical analyses were performed using GraphPad Prism
2.01 Software (GraphPad Software, San Diego, CA).Acknowledgments
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